Growth hormone secretion pathway

The term **"Growth hormone secretion pathway"** does **not refer to a single molecular target**, but rather describes the complex physiological and molecular processes that regulate the synthesis and release of growth hormone from somatotropic cells in the anterior pituitary gland. This process is primarily controlled by two hypothalamic hormones: **growth hormone-releasing hormone** (GHRH), which stimulates GH release; and **somatostatin**, which inhibits it. The released GH acts on various tissues throughout the body via its receptor—the **growth hormone receptor**—and also stimulates production of insulin-like growth factor 1 (**IGF‑1**) in peripheral tissues such as liver[1][2][3]. The system operates through intricate feedback loops involving GHRH, somatostatin, GH itself, and IGF‑1.\n\nBecause this entry refers to an entire regulatory *pathway* rather than a discrete protein/receptor/enzyme/transporter/etc., it is considered incorrect as a therapeutic target name under standard conventions. Drugs do not directly bind or modulate an abstract “secretion pathway,” but instead act on individual components such as receptors for GHRH or somatostatin[2].\n\n> In summary: “Growth hormone secretion pathway” is *not* a canonical molecular target; it represents an integrated neuroendocrine regulatory network controlling growth hormone output from the pituitary gland[2].

Other names

Growth hormone secretionGrowth hormone pathwayGH secretion pathwaySomatotropic axis (sometimes used in literature)